NervGen Pharma (TSE:NGEN) has released an update.
NervGen Pharma, a biotech firm focusing on nervous system repair, has recently issued 45,000 stock options to its employees and consultants as incentives, with specific vesting periods and exercise terms. The company is currently advancing its lead drug candidate, NVG-291, through clinical trials and is exploring a new candidate, NVG-300, for various neurological conditions.
For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.
